MedTrace Logo

Open-Label Extension Study of ASTORIA

NCT05516875 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-10-15

No results posted yet for this study

Summary

This current open-label extension (OLE) study (JM-010CS-OL) will explore the safety and tolerability of long-term administration of JM-010 of patients who completed 12-week treatment of Phase 2 (JM-010CS03) study.

Conditions

  • Dyskinesias

Interventions

DRUG

JM-010

JM-010

Sponsors & Collaborators

  • Contera Pharma A/S

    lead INDUSTRY

Principal Investigators

  • Contera Clinical Development · Contera Pharma

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-19
Primary Completion
2024-05-22
Completion
2024-06-27

Countries

  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05516875 on ClinicalTrials.gov